{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:24:26Z","timestamp":1773836666738,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["8053\u201000083B"],"award-info":[{"award-number":["8053\u201000083B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polymorphism of the <jats:italic>CYP2D6<\/jats:italic> gene leads to substantial interindividual variability in CYP2D6 enzyme activity. Despite improvements in prediction of CYP2D6 activity based on genotype information, large interindividual variability within <jats:italic>CYP2D6<\/jats:italic> genotypes remains and ethnicity could be a contributing factor. The aim of this study was to investigate interethnic differences in CYP2D6 activity using clinical datasets of three CYP2D6 substrates: (i) brexpiprazole (<jats:italic>N<\/jats:italic>\u00a0=\u00a0476), (ii) tedatioxetine (<jats:italic>N<\/jats:italic>\u00a0=\u00a0500), and (iii) vortioxetine (<jats:italic>N<\/jats:italic>\u00a0=\u00a01073). The CYP2D6 activity of all individuals in the dataset was estimated through population pharmacokinetic analyses as previously reported. Individuals were assigned a CYP2D6 phenotype and <jats:italic>CYP2D6<\/jats:italic> genotype group based on their <jats:italic>CYP2D6<\/jats:italic> genotype and interethnic differences were investigated within each group. Among individuals categorized as CYP2D6 normal metabolizers, African Americans had a lower CYP2D6 activity compared to Asians (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) and in the tedatioxetine and vortioxetine analyses also compared to Whites (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Among CYP2D6 intermediate metabolizers, interethnic differences were also observed, but the findings were not consistent across the substrates. Asian carriers of <jats:italic>CYP2D6<\/jats:italic> decreased function alleles tended to exhibit higher CYP2D6 activity compared to Whites and African Americans. The observed interethnic differences within the CYP2D6 phenotype and genotype groups appeared to be driven by differences in <jats:italic>CYP2D6<\/jats:italic> allele frequencies across ethnicities rather than interethnic differences in enzyme activity for individuals carrying identical <jats:italic>CYP2D6<\/jats:italic> genotypes.<\/jats:p>","DOI":"10.1111\/cts.13506","type":"journal-article","created":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T07:12:30Z","timestamp":1677913950000},"page":"1012-1020","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Does ethnicity impact <i>CYP2D6<\/i> genotype\u2013phenotype relationships?"],"prefix":"10.1111","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0266-4065","authenticated-orcid":false,"given":"Trine","family":"Frederiksen","sequence":"first","affiliation":[{"name":"Department of Experimental Medicine H. Lundbeck A\/S  Valby Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Areberg","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine H. Lundbeck A\/S  Valby Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine H. Lundbeck A\/S  Valby Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-4389","authenticated-orcid":false,"given":"Tore Bjerregaard","family":"Stage","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Br\u00f8sen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark  Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00750-8"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.80"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm8020015"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200215666140202215316"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100406"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104620"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.650750"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1972"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12635"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2791"},{"key":"e_1_2_10_12_1","unstructured":"Otsuka Pharmaceutical Co Ltd.Prescribing Information for Rexulti (brexpiprazole) tablets.2020http:\/\/www.accessdata.fda.gov"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2021.1897898"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2021.1890275"},{"key":"e_1_2_10_15_1","unstructured":"US Drug label.TRINTELLIX (vortioxetine) tablets for oral use.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/204447s017lbl.pdf"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2012.00886.x"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12256"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12692"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12665"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200110000-00004"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddt417"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.044610"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488407779422302"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2019.07.003"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2017.03.007"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2017.05.018"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13506","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.13506","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T14:59:59Z","timestamp":1692457199000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/cts.13506"],"URL":"https:\/\/doi.org\/10.1111\/cts.13506","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"assertion":[{"value":"2023-01-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}